MedPath

ASPEN GLOBAL INCORPORATED

🇲🇺Mauritius
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:9
Completed:1

Trial Phases

3 Phases

Phase 1:9
Phase 3:1
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
9 (81.8%)
Phase 3
1 (9.1%)
Phase 4
1 (9.1%)

A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.

Phase 4
Completed
Conditions
Injection Site Reaction
Interventions
First Posted Date
2019-02-15
Last Posted Date
2019-02-15
Lead Sponsor
Aspen Global Incorporated
Target Recruit Count
15
Registration Number
NCT03841396

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Phase 3
Terminated
Conditions
Heparin-induced Thrombocytopenia
Interventions
First Posted Date
2019-01-18
Last Posted Date
2022-12-08
Lead Sponsor
Aspen Global Incorporated
Target Recruit Count
7
Registration Number
NCT03809481
Locations
🇺🇸

Shands University of Florida, Gainesville, Florida, United States

🇺🇸

University of Minnesota Medical Center, Minneapolis, Minnesota, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 32 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.